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Abstract.  In many organs the vascular endothelium 
forms a barrier which impedes the free diffusion of 
large molecules. The mechanism by which protein 
hormones are transported through the endothelial cells 
to reach their target cells is unknown.  We have exam- 
ined the transport of human chorionic gonadotropin 
(hCG) in rat testicular microvasculature by electron 
microscopy and by analysing the transfer of radiola- 
beled hormone and antibodies.  Surprisingly,  we have 
observed that the same receptor molecule which is 
present in target Leydig cells is also involved in trans- 
cytosis through the endothelial cells. The hormone 
was internalized by coated pits and vesicles on the lu- 
minal  side of the endothelium.  It was then localized in 
the endosomal compartment and subsequently ap- 
peared to be delivered by smooth vesicles into the 
subendothelial space. Moreover, anti-LH/hCG receptor 
antibodies were efficiently transported via the same 
system and delivered into the interstitial  space. If 
generalized,  these observations may define a new level 
of modulation of hormone action and may be of im- 
portance for drug targeting into the numerous organs 
which are responsive to the various protein hormones. 
S 
YNTHESIS and secretion into the bloodstream of protein 
hormones  have  been  extensively  studied  (review  in 
Baulieu and Kelly, 1990). More recently experimental 
studies have focused on the interaction of the hormones with 
their target cells through specific receptors and on the ensu- 
ing activation of intracellular  signalling pathways (review in 
Kahn,  1989). Surprisingly,  almost nothing is known on the 
intermediary steps,  i.e., the passage of hormones from the 
bloodstream into the interstitial  space.  Most capillary  en- 
dothelial beds have occluding or fight intercellular junctions 
that do not permit the free diffusion of molecules of the size 
of protein hormones (review in Simionescu and Simionescu, 
1991). It is thus necessary to hypothesize for these hormones 
the existence of as yet non identified transendothelial  trans- 
port mechanisms.  We have examined the passage of human 
chorionic gonadotropin  (hOG) ~ through  the continuous en- 
dothelium of the testicular microvasculature.  We have ob- 
served  that  this  transport  occurs  through  a  transcytosis 
mechanism involving the LH/hCG receptor.  New regulatory 
mechanisms may thus exist at this level and may also have 
important consequences for the practicability  of drug tar- 
geting. 
Address all correspondence to E. Milgrom, INSERM U. 13.5, H6pital de 
Bic6tre, 78, Rue du General Leclerc, 94270 Le Kremlin-Bic6tre, France. 
1. Abbreviations  used in this paper: hCG, human choriogonadotropin; LH, 
luteinizing hormone;  TSH, thyroid-stimulating hormone. 
Materials and Methods 
Animals 
The experiments were carded out on male Wistar rats of about 200 g kept 
in standard housing and feeding conditions. 
Chemicals 
Human choriogonadotropin (hCG), iodination grade, was purchased from 
UCB-Bioproducts  (Braine-l~llend,  Belgium),  BSA  (fraction  V)  and 
1,2,4,6-tetrachloro-3a,  6a-diphenylglycouril  were  obtained  from  Sigma 
Immunochemicals  (St. Louis,  MO).  Colloidal  gold solutions were from 
Bio-Cell Research Laboratories  (Cardiff, UK). 
Antibodies 
Mouse monoclonai anti-porcine  luteinizing hormone  (LH)/hCG receptor 
antibody  729  (LHM29)  and  mouse  monoclonal  anti-human  thyroid- 
stimulating hormone (TSH) receptor antibody 51 (TSH51) were produced 
in mouse nscites and purified on protein A-Sepharose  CL-4B (Pharmacia 
LKB Biotechnology AB,  Uppsala,  Sweden) as previously described  (Vu 
Hai et al., 1990; Loosfelt et al., 1992). The monoclonal antibody LHM29 
raised against the pig LH/hCG receptor (Loosfelt et ai., 1989) was chosen 
for its high cross-reactivity with rat hCG/LH receptor (Vu Hai et al., 1990). 
Mouse monoclonal  anti-idiotypic  antibody  10 (IDA 10) (Legrain et al., 
1983) was produced from a hybridoma kindly supplied by Dr. E  Legrain 
(Unit6 de G6n6tique Somatique, Institut Pasteur, Paris). All monoclonal an- 
tibodies used in the present study were of the IgG1 isotype. 
Tracers 
Radioiodinated Proteins.  [12SI]hCG (sp act 82.2 #Ci/#g) was from NEN 
Research Products (Boston, MA). LHR729, TSHR51, and BSA were radio- 
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scribed (Fraker and Speck,  1978).  Their specific radioactivity was >30 
/~Ci//zg. The radioactive proteins were used at a final concentration of 0.1 
/zg/ml PBS, pH 7.3, containing 1 mg/mi of ovalbumin. 
Gold Conjugates. LHR729-Au5 m, TSHR51-Au5 m, hCG-Au5 nm, hCG- 
Aul0 am, hCG-Au15 ~m, and BSA-Au10  nm complexes were prepared accord- 
ing to standard methods (DeMey,  1986).  For perfusion experiments the 
gold complexes were resuspended in PBS, pH 7.3, containing 1 mg/ml oval- 
bumin to a final concentration corresponding to A~m  -  0.1 for gold par- 
ticles of 5 nm in diameter, to A~m  -- 0.2 for gold particles of 10 nm in 
lcm  diameter and to A~o nm =  0.3 for gold particles of 15 um in diameter. In 
some experiments with BSA-Aul0 m  the concentration of the tracer was 
A~0~n~ =  2. The gold conjugates appeared as monodisperse when exam- 
ined by electron microscopy. As previously described (Saiesse et ai., 1989; 
Ghinea et al., 1992) both hormone and anti-receptor antibodies coupled to 
colloidal gold preserve their biological activities. The gold-antibody com- 
plexes do not sterically hinder the binding of the gold-hormone conjugates 
and vice versa (Ghinea et ai.,  1992). 
Perfus/on  Protoco/s.  The  a,imals  were  anesthesized  with  an  in- 
traperitoneal injection of 5% Nesdonai (Specia, Paris) (0.25 mi/100 g body 
weight). After thoracotomy and exposure of  the heart the perfusion was car- 
ried out in an open circuit using the left ventricle as the inlet and the opened 
right atrium as the outlet. The vasculature was washed free of blood by per- 
fusion with '~20 ml of prewarmed (37°C) PBS, pH 7.3, supplemented with 
14 mM glucose and gassed with 95 % 02 and 5 % CO2. The perfusate was 
given under a constant pressure of 75 cm H20 at a flow rate of 5 ml/min 
for 10 rain. The tracers were then added to the perfusate and maintained 
in the circulation for various periods of time (5,  10,  15, and 20 rain). The 
excess of unbound markers was washed out by perfusion with '~50 mi cold 
(4°C) PBS, pH 7.3 (in order to stop the transport process), in the same con- 
ditions as above. In some experiments the testes were removed, homoge- 
nized for counting of  radioactivity and for immunoaflinity chromatography. 
In other experiments the testes were fixed in situ for 15 rain and then over- 
night with a mixture of  2.5 % glutaraldehyde and 5 % formaldehyde in 0.1 M 
HCl-sodium cacodylate buffer, pH 7.2. In several experiments fragments of 
lung, diaphragm, heart, and epidydimal fat were excised and fixed for 90 
rain in the same fixative. 
Controls. The specificity of the labeling by [125I]hCG and hCG-Aulo m 
was assayed by perfusing the tracers in the presence of an excess of unla- 
beled hormone (45/~g of hCG/mi PBS, pH 7.3, containing I mg/mi ovaibu- 
rain).  The specificity of the immunolabeling of LH/hCG receptors was 
tested by perfusion with either LHR729-Au5 nm in the presence of 0.1 rag/ 
ml unlabeled LHR729 or with TSHR51-Au5 ~m (used as a non-related con- 
trol monoclonai antibody-gold complex). 
1Issue Homogenization and Receptor A~inity Chromatography. Dur- 
ing its transport towards the Leydig cells, hCG can either bind to the en- 
dotheliai or to the Leydig cell receptors or be free (i.e., localized in the in- 
terstitial fluid). To follow the fate of the hormone we have perfused in situ 
the rat vasculature (see above) with [125I]hCG. After 20 rain of perfusion 
(at 37 ° or 4°C) the intravascular [123I]hCG was washed out with cold (4°C) 
PBS, pH 7.3, containing 1 mg/ml ovalbumin. The testes were homogenized 
at 4°C with PBS, pH 7.3, containing a cocktail of protease inhibitors (1 mM 
benzamidine,  1  mM phenylmethylsulfonylfluoride, 5  mM  leupeptin,  1 
/zg/mi pepstatin, 40/zg/rnl aprotinin, and 100/zg/mi hacitracin) (buffer A). 
All further steps were carried out at 4°C. The homogenate was cold (4°C) 
centrifuged for 60 rain at 105,000  g and the supernatant (SO saved. The 
pellet was extracted overnight with 1% Triton X-100 in buffer A and cen- 
trifuged for 60 min at 105,000 g. The resultant 105,000 g supernatant ($2) 
was presumed to contain the membrane bound hormone (i.e., [t25I]hCG- 
LH/hCG receptor complexes). The supernatants Si and $2 were diluted 
with 2  volumes of buffer A  and  then applied  separately onto an  im- 
munomatrix column (0.25  rni of LHR729-Afligal  10) (Vu Hai,  1990) at a 
flow rate of 2 ml/h. The gel was finally washed with 50 volumes of buffer 
A and counted for radioactivity. IDA 10-Affigel 10 (Lograin et al.,  1983) 
was used as a non-receptor related immunomatrix control. 
Effect of the Hormone on the Transcytosis of LHR729 through the 
Endothelium. The transendothelial transport of [1~I]LHIU29,  fluorescein- 
LHR729,  and LHR729-AU5 m  was studied by perfusion in situ in the pres- 
ence or in the absence of  4.5/~g of hCG/mi of PBS containing I mg/ml oval- 
bumin. TSHRS1  (Loosfelt et al.,  1992) was used as a control non-related 
monoclonal antibody. 
Immunofluorescenee Microscopy, After in situ perfusion with fluores- 
cein-LHR729 (prepared according to Melan and Sluder, 1992) the testicular 
vasculature was fixed by perfusion for 30 rain and then overnight with 3.5% 
formaldehyde in HCl-sodium-cacodylate, pH 7.2, buffer containing 10% 
sucrose. Cryostat sections (5-7 pro) were prepared from fixed rat testes and 
were collected on glass slides. The sections were examined in a Leitz or- 
thoplan microscope using epi-illumination. Color and black and white pho- 
tographs were taken with Kodak T-Max 400. Fluorescein-TSH51 (prepared 
according to Melan and Sluder,  1992)  was used as a control non-related 
monoclonai antibody. 
Electron Microscopy. Specimens collected from the fixed testes were cut 
into ~1 nun  3 blocks, and postfixed at 4°C for 90 rain in 1% OsO4, 0.1 M 
HCl-sodium cacodylate, pH 7.2, buffer. The blocks were stained with 0.5 % 
uranyl acetate, dehydrated in graded ethanol and embedded in Epon 812. 
Sections ('~60 run), obtained with a Reichert OmUc ultramicrotome were 
stained with uranyl acetate and lead citrate and examined at 80 IN in a Sie- 
mens Elmiscop I01  microscope. 
Capillaries,  arterioles, and venules were identified as previously de- 
scribed (Simionescu and Simionescu, 1984). 
Quantitation.  A triplicate experiment was carried out to examine the 
changes provoked by hormone administration on the distribution and on the 
transcytosis of LHR729-Au5 m- Ultrathin sections were cut from three ran- 
domiy selected blocks of each experiment and 45 capillary profiles (120 en- 
dothelial cells) were examined. A total area of 1,500  pm  2 of endothelial 
cells was examined. Gold particles present on random cell profiles were al- 
located to one of the following organelles: luminal plasma membrane, 
coated pits associated with both luminal and ahluminal endothelial fronts, 
coated vesicles, endosomes (smooth vesicles and tubular structures), mul- 
tivesicular bodies, abluminal plasma membrane, and subendothelial space 
(endothelial basal lamina included). The percentage of gold particles as- 
sociated with each organelle was determined. A total number of 750-800 
gold particles were allocated to the different structures, in each experiment. 
Results 
Transcytosis Pathway of  hCG in the Microvascular 
Endothelium of  Rat Testis 
To examine the route of the hormone through  the vascular 
endothelium we coupled hCG to gold particles of various di- 
ameters, perfused rats at 37°C, and collected testes after var- 
ious times ofperfusion (5, 10, 15, and 20 rain). We examined 
by electron microscopy the arteriolar, capillary,  and venular 
endothelial cells. In all these cells and irrespective of particle 
size, the tracers were internalized and transcytosed by simi- 
lar routes. 
After 5  rain  of perfusion,  the  gold  particles  were dis- 
tributed on the plasmalemma proper, the coated pits, and the 
coated vesicles of the luminal surface of the endothelium 
(Fig.  1 a). After 15 rain of perfusion the labeled hormone 
was also present in the tubulovesicular endosomes (Fig. 1 b) 
and in large smooth vesicles located near the abluminal side 
of the endothelium (Fig.  1 c). At later stages (after 20 rain 
of perfusion)  the  hormone-gold  complex  was  located  in 
large smooth vesicles open to the subendothelial space (Fig. 
1 e). A large amount of free gold-labeled hCG was observed 
in  the  abluminal  space  and  some  tracer  was  apparently 
bound to Leydig cell membranes (not illustrated).  Some par- 
ticles were seen in the abluminal coated pits corresponding 
probably to the re-internalized hormone (Fig.  1 f).  More- 
over, a small proportion of the hCG-Au conjugate was pres- 
ent in the multivesicular bodies (Fig.  1, d and f) suggesting 
an  accessory  pathway  of degradation  of the hormone.  In 
these highly pleomorphic structures  the gold particles were 
concentrated on the limiting membrane and their tubular ex- 
tensions (Fig.  1 d).  In most cases, the internal  vesicles of 
these vacuoles were devoid of labeling (Fig.  1, d and e). No 
transport  of hCG-gold  complexes  was  observed  via  plas- 
malemmal vesicles or through the junctions (Fig. 1 a) of en- 
dothelial cells. 
The Journal  of Cell Biology,  Volume 125, 1994  88 Figure L  Transcytosis of hCG-Au5 ,m through the endothelial cells of rat testicular capillaries. (a) After 5 re_in of perfusion with hCG- 
Aus,m the tracer marks the luminal plasma membrane (pro), the coated pits (cp), and the coated vesicles (cv), but fails to label the plas- 
malemmal vesicles (vt) open to the capillary lumen and the endothelial junctions q).  (b-d) After 15 rain of perfusion the gold-labeled 
hormone is detected in the tubular (re) and vesicular (ve) endosomes (b) and in large smooth vesicles (SV) located near the abluminal 
side of the endothelium (c). Some hormone is present in the multivesicular bodies (mvb) (d). (e and f) After 20 rain of perfusion hCG- 
AUs,m is delivered into the interstitial space (is) via smooth vesicles (Sir) (e). Some of the tracer is associated with the plasma membrane 
(pro) and the coated pits (cp) of the abluminal cell surface of the endothelium (f). (Inset) Control perfusion with BSA-Au5  m. The gold- 
labeled albumin was perfused for 5 rnin at a concentration 20-fold higher than the concentration of hCG-Au5 m  1  (A~o~ =  2 and A~m,m 
=  0.1, respectively). Some gold particles are present in the plasmalemmal vesicles (vt) open to the capillary lumen (L). End, endothelial 
cell. Bar, 0.1 ttm. The Journal of Cell Biology, Volume 125,  1994  90 As a control we used BSA coupled to colloidal gold parti- 
cles. This tracer has been shown in the rat to cross via plas- 
malemmal vesicles  the  continuous endothelium of heart, 
lung, and adipose tissue (review in Simionescu and Simi- 
onescu, 1991). When the BSA-gold conjugate was perfused 
through the testes at a concentration similar to that of the 
hCG-gold complex, only rare particles were seen on the 
plasmalemma proper and in the plasmalemmal vesicles open 
to the luminal side of the endothelium (data not shown). At 
a 20-fold higher concentration of BSA-gold particles some 
of them were taken up by the plasmalemmal vesicles (never 
exceeding four particles per vesicle) (Fig. 1 a, inset) suggest- 
ing a bulk phase uptake. No BSA was seen passing through 
the endothelial junctions. 
The LH/hCG Receptor Is Involved 
in Hormone Transcytosis 
Observation of hCG-gold complexes in the endothelial cells 
of testes suggested that they interacted with a membrane pro- 
tein which tended to accumulate in coated pits and coated 
vesicles. The similarity of this observation with the initial 
steps of hormone interaction with Leydig cells (Ghinea et 
al., 1992) led us to ask the question if  the same receptor mol- 
ecule could be involved in both cases. 
We thus used a  monoclonal antibody (LHR729) raised 
against the Leydig cell LH/hCG receptor and conjugated it 
to colloidal gold. Perfusion experiments were performed as 
above.  After 5 rain of perfusion at 37°C the antibody-gold 
complex was internalized by the endothelium. Internaliza- 
tion occurred via coated pits (Fig. 2 a) and coated vesicles 
in a way very similar to that previously observed for hor- 
mone-gold conjugate. After 15 min the probe was also ob- 
served in tubulo-vesicular endosomes and in large smooth 
vesicles located near the abluminal cell surface of the en- 
dothelium (Fig. 2 b). A small number of gold particles were 
seen in the subendothelial space. At longer times of perfu- 
sion (20 rain) the proportion of the particles delivered into 
the subendothelial space via smooth vesicles open to the ab- 
luminal front increased as well as after hormone administra- 
tion (Fig. 2 c, and Table I). 
As  in  the  case  of  hormone  transcytosis,  some  anti- 
body-gold complex labeled the abluminal coated pits and 
vesicles (Fig. 2 d) suggesting re-internalization of the anti- 
body and thus, the recycling of the receptor. 
Hormone and Receptor Molecules Have Similar 
Pathways of Transcytosis 
To follow ultrastructurally on the same sections the cellular 
traffic of  hormone and receptor we perfused in situ the testic- 
ular vasculature with a mixture of labeled hormone (hCG- 
Au~0 m)  and of differently labeled anti-receptor  antibody 
Table I. Effect of  hCG on the Transendothelial Transport 
of LHR729-AUs~m in Rat Testicular Capillaries 
LHR729-Au5 m Particles 
Cellular organelles and 
subendothelial space  -  hCG  +  hCG 
Luminal plasmalemma  5.0  2.2 
Luminal-coated pits  24.8  16.5 
Coated vesicles  25.2  28.6 
Endosomal structures 
(vesicles, tubules)  37.2  27.1 
Multivesicular bodies  1.9  2.4 
Abluminal plasmalemma  0.1  2.0 
Abluminal-coated pits  0.2  4.9 
Subendothelial space  5.6  16.2 
The labeled antibody was perfused for 20 rain as described in the absence or 
presence of hCG. The testes were examined by electron microscopy and the 
percentage of gold particles associated with each organelle was determined (see 
Materials and Methods). A total number of 2,400 and 2,250 particles were ob- 
served in the experiments in presence and in absence of hCG, respectively. 
(LHR729-Aus ~).  The results of these double labeling ex- 
periments are shown in Fig. 3. 
The hormone and the receptor molecules were colocalized 
on the luminal plasma membrane, in coated pits and vesicles, 
in tubulo-vesicular endosomes (Fig. 3, a and b), multivesicu- 
lar bodies (Fig. 3 c) and smooth vesicles located near the ab- 
luminal front of the endothelium. After 20 rain of perfusion 
both hormone and anti-receptor antibody were delivered 
into the subendothelial space (Fig. 3 d). Some particles of 
both tracers labeled the abluminal plasma membrane and its 
associated coated pits (Fig. 3 d). 
These results suggested that the hormone was bound by the 
LH/hCG receptor on the luminal surface of  endothelial cells, 
that the complexes were transcytosed and that the hormone 
was freed into the subendothelial space. Moreover, an anti- 
body against the receptor could follow the same route and 
its transport through the endothelial cells could apparently 
be accelerated by administration of hormone. 
Specificity of the Receptor-mediated Endothelial 
Transcytosis of hCG 
To show that the transendothelial transfer of  hCG was satura- 
ble we perfused the testes with hCG-gold complexes in the 
presence of a high excess of hCG (45 #g hCG/ml perfusate). 
This largely suppressed  the binding of hCG-gold to  the 
endothelial surface receptor  and its  subsequent transport 
(Fig. 4 a). 
Tissue  specificity  was  studied  using  both  hCG  and 
LHR729-gold particles. In organs having a continuous vas- 
cular endothelium (heart, lung, diaphragm, and epidydimal 
fat) both types of complexes failed to label the luminal plas- 
Figure 2.  Transcytosis of anti-LH/hCG receptor monoclonal antibody 729-gold complex in the capillary endothelium of rat testis.  (a) 
After 5 min of perfusion LHR729-Au5 ~  the tracer is internalized by the endothelium (End) via the coated pits (cp) open to the capillary 
lumen (L). (b) After 15 min of perfizsion, the tracer particles are observed in the coated vesicles (cv), tubular (te), and vesicular (ve) endo- 
somes, and in large smooth vesicles (Sir) located near the abluminal front of the endothelium (End).  A  small number of gold particles 
(arrows) are present in the interstitial space (is). (c and d) After 20 rain of perfusion in the presence of 4.5/~g of hCG/ml the antibody-gold 
complex is delivered into the interstitial space (is) via smooth vesicles (SV) open to the abluminal cell surface of the endothelium (End) 
(c).  Some tracer particles are associated with the abluminal coated pits (cp) and coated vesicles (cv) (d).  va, abluminal plasmalemmal 
vesicle. Bar, 0.1  ~m. 
Ghinea et al. Transendothelial Transport of hCG  91 Figure 3. Comparison of  the pathways  of  hormone and monoclonal anti-receptor antibody in testicular capillary endothelium. Double label- 
ing with hCG-Aul0  ~m and LHR729-Au5  m. The testes were perfused in situ with a mixture of both tracers for 5 rain (a), 15 rain (b and 
c), and 20 rain (d) at 37°C. Note that both markers label the same structures suggesting common transcytosis pathways for receptor and 
hormone (arrows).  Note also the increased transfer of the antibody in the presence of hormone (compare with Fig. 2). cp, coated pit; 
cv, coated vesicle; e, endothelium; is, interstitial space;j, endothelial junction; mvb,  multivesicular body; pm, plasma membrane; re, tubular 
endosome; vo, abluminal plasmalemmal vesicle; v,, luminal plasmalemmal vesicle. Bar, 0.1 #m. 
malemma proper and its associated coated pits.  Rarely, a 
very limited non-specific (fluid-phase) uptake of the tracers 
was observed occurring through plasmalemmal vesicles (at 
most one to two particles/vesicle) (Fig. 4, b and c). 
Antibody specificity was studied by perfusing the testes 
with a gold-tagged monoclonal anti-TSH receptor antibody. 
In this experiment, some rare gold particles were observed 
in the plasmalemmal vesicles of endothelial cells (Fig. 4 d). 
Species specificity was analyzed by perfusing gold-tagged 
anti-LH/hCG receptor antibodies in pigs (LHR38 antibody) 
and in rabbits (LHR285 antibody). In both cases the labeling 
patterns of the endothelial cells in the testes were similar to 
those described above in rats (Ghinea, N.,  M.  T.  Groyer- 
Picard, and E. Milgrom, manuscript in preparation). 
The Journal of Cell Biology,  Volume 125, 1994  92 Figure 4. Specificity of  the transcytosis ofhCG and of  anti-LH/hCG receptor  antibody. (a and b) Tissue specificity was studied by analyzing 
the distribution of hCG-Aul5  m (a) and of LHR729-Au5  ~m (b) in the microvasculature of the heart (myocardium). The tracers ware per- 
fused in situ for 20 min at 37°C. Note the very limited non-specific uptake of both tracers occurring via luminal plasmalemmal vesicles 
(vt). Similar observations were recorded in other organs having a continuous capillary endothelium (lung, diaphragm, epidydimal fat). 
(c) The specificity of the transcytosis of antibodies was studied by perfusing the rat testes for 20 min at 37°C with mouse anti-human 
TSH receptor monoclonal antibody (TSH51) coupled to colloidal gold. Note that the TSH-Aus  m is transcytosed in fluid-phase via the 
plasmalemmal vesicles, j, endothelial junction; L, lumen; va, abluminal plasmalemmal vesicle. Bar, 0.1 #m. 
Transendothelial Transport of~l-labeled hCG and 
Anti-receptor Antibody 
Electron microscopic observations have allowed a detailed 
description of the cellular pathways which are followed for 
the hormone and the anti-receptor antibody. However, this 
method could not yield quantitative data and could not assess 
the  possibility  that  the  hormone delivered to  the  suben- 
dothelial space might be complexed to the extracellular do- 
main of the receptor. To answer these questions we perfused 
the testes for 20 min with 12SI-labeled hormone. After ex- 
tensive washing, we measured the free and the membrane- 
bound Triton X-100 extractable radioactivity. The latter rep- 
resented the receptor bound hormone since it was displaced 
by coperfusion with an excess of unlabeled hormone and 
since 93 % of it was retained by chromatography through an 
immunomatrix containing LHR729 antibody (Table 1I). The 
Triton-extractable radioactivity obtained after perfusion at 
low temperature most likely represents the hormone bound 
to the endothelial receptor. At 37°C transendothelial trans- 
port had occurred and there was in addition some binding to 
the Leydig cell receptors (Table 11). 
The soluble [lZSI]hCG present in the testes probably rep- 
resented the hormone which had been transported through 
the endothelium. This is supported by electron microscopy 
analysis which shows that unbound hCG-gold complexes are 
present in the subendothelial space (see Figs. 1 and 3). There 
was very little contamination by residual radioactive hor- 
mone  remaining  inside  the  blood  vessels  since  soluble 
p25I]hCG was largely suppressed (Table 17) by coperfusion 
with unlabeled hormone or by perfusion at low temperature 
(blood contamination would not have been decreased by ex- 
cess unlabeled hormone or by low temperature). Thus the 
soluble [~2q]hCG most likely represented a major fraction 
of the hormone which has passed the endothelial barrier (al- 
though some of this hormone has become attached to Leydig 
cell membranes) (see above). 
Based on this assessment, the transport was negligible at 
4°C. It was saturable, as shown by its suppression in the pres- 
ence of an excess of  unlabeled hormone (Table lI). The solu- 
Table II.  Transendothelial Transport of  [lzSI]hCG in 
the Rat Testes 
Membrane-bound hormone 
Soluble hormone 
Triton  X-100 
membrane extract  Total 
Experimental  (cpm/g wet  Receptor  (cpm/g wet  Receptor 
conditions  tissue)  bound  tissue)  bound 
%  % 
37eC 
-  hCG  2,700  93.2  2,200  1.6 
+  hCG  400  360 
4oc 
-  hCG  2,300  200 
+  hCG  350  130 
[nSI]hCG was perfused  for 20 min at 4 ° or 37°C in the absence or in the 
presence of an excess of unlabeled hormone (see Materials and Methods). Al~er 
washing by perf~sion of PBS, testicular soluble, and membrane fractions were 
prepared. The latter was extracted by Triton X-100. Some of the extracts were 
chromatographed on an immunomatrix containing anti-LH/hCG receptor anti- 
body (see Materials and Methods). The fraction of  the hormone retained on the 
immunomatrix was considered as receptor bound. The Table shows one of the 
two experiments which yielded similar results. 
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Proteins: Anti-LH/hCG Receptor Antibody, Nonspecific 
(anti- TSH receptor) Antibody, and Albumin* 
Radioactivity  (epm/g wet tissue) 
Triton X-100 
Tracer  Soluble tracer  membrane extract 
-  hCG 
pz~I]LHR729  2,600  12,850 
[1~I]TSHR51  580  3,220 
[nsI]albllmin  930  5,900 
+  hCG 
[1~I]LHR729  4,200  61,800 
[125I]TSHR51  700  3,740 
[12sI]albumin  875  5,230 
* Perfusion experiments  were  performed  as described  in Table  II and in the 
Materials and Methods section. 
ble [~z~I]hCG might have been complexed with the ectodo- 
main  of the  receptor.  Cleavage of the  poly-IgA receptor 
during the transepithelial transport of its ligand has been de- 
scribed (Mostov et al., 1980; Solari et al., 1989). To exam- 
ine this hypothesis we perfused testes at 37°C, recovered the 
soluble fraction and applied it to an immunomatrix contain- 
ing the LHR729 anti-receptor antibody (this antibody has 
been shown to  recognize the extracellular domain of the 
receptor (Vu Hai et al.,  1990)). Only  1.6% of the soluble 
[t25I]hCG did bind to the anti-receptor antibody suggesting 
that the hormone which has been transported through the en- 
dothelial  barrier  was  not  complexed to  the  receptor ec- 
todomain. 
Since electron microscopic experiments have suggested a 
transendothelial transfer of the anti-LH/hCG receptor anti- 
body, we also labeled the latter with [1~I-] and used it for 
perfusion experiments. For comparison we did similar per- 
fusions with a non-spocific antibody (~25I--labeled anti-TSH 
receptor antibody, TSHR51) and with [t~I-]albumin.  The 
experiments were performed both in the presence and in the 
absence of hCG. 
As shown in Table 11I some of the anti-LH/hCG receptor 
antibody was recovered in the Triton X-100 membrane ex- 
tract. This fraction could correspond to antibodies bound to 
the  receptor.  This  fraction was  increased  ~60%  by co- 
perfusion of the antibody with hCG. This result may be ex- 
plained  by an  increased transendothelial transport  in  the 
presence of the hormone (see also Figs. 2 and 3) leading to 
an increased binding of antibodies to Leydig cell receptors. 
No significant amounts of  the albumin and of  the non specific 
antibody were recovered in this Triton X-100 membrane ex- 
tract (Table m). Coperfusion with hCG did not affect this 
fraction. 
As discussed above in the case of pzq-]hCG, we consid- 
ered the  soluble  [~I-]LHR729  recovered in the testes  as 
representing a  major fraction of the antibodies which had 
crossed the endothelial barrier. We thus observed that the 
transport of the anti-LH/hCG receptor antibody was mark- 
edly increased (approximately fivefold) by coperfusion with 
hCG. It was also 20-fold more efficient than that of the con- 
trol non specific antibody and 12-fold more efficient  than that 
of albumin. 
To  further  examine  the  transport  of the  anti-LH/hCG 
receptor antibody and its subsequent binding to Leydig cell 
receptors we labeled this antibody with fluorescein, perfused 
it  and  examined by  light  microscopy the  distribution  of 
fluorescence in  the  testes  (Fig.  5).  AS expected,  the en- 
dothelial cells were strongly labeled (Fig. 5 a) and the anti- 
body had reached the surface of the Leydig cells (Fig. 5 b). 
When  a  control fluorescein-labeled monoclonal antibody 
(Fluorescein-TSH51) was used only a weak signal was de- 
Figure 5. Intratesticular transfer of fluorescein-labeled anti-LH/hCG receptor antibody (LHR729). The tracer was perfused for 20 rain 
at 37"C in the presence of 4.5 #g of hCG/ml. (a) Arteriolar endothelium (End) stained by the fluoreseein-LHR729 conjugate. (b) The 
fluorescent probe is specifically associated with the Leydig cells and with the capillary endothelium (c). No fluorescence is detected at 
the level of the seminiferous tubules (st). Bar, 10/~m. 
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Discussion 
The microvascular endothelium forms a thin and continuous 
layer of squamous epithelial cells which separates the blood 
from the interstitial fluid. Endothelial cells are polarized and 
linked one to another by junctional complexes (tight and gap 
junctions)  which ensure the continuity and mark the tran- 
sition between the luminal  (blood)  and abluminal  fronts. 
Ultrastructural  and cytochemical studies (review in Simio- 
nescu and Simionescu, 1991) have shown that the microvas- 
cular endothelium constitutes a major barrier for the bidirec- 
tional exchanges of  macromolecules between the plasma and 
the interstitial  fluid.  In vivo experiments  involving injec- 
tion of labeled proteins have confirmed this morphological 
finding showing that several hours are required for vascular/ 
interstitial equilibration of radioactive plasma proteins (Lar- 
son et al., 1984; Powers and Bell, 1990; Ghitescu and Ben- 
dayan,  1992). 
All these  studies involved proteins  present  in relatively 
high  concentration  in  blood.  The  route  of the  transen- 
dothelial transport of these proteins has also been studied. 
It was shown that they reach the interstitial space via plas- 
malemmal  vesicles  and  transendothelial  channels  (Simi- 
onescu et al.,  1975). This process  involves a non-specific 
fluid phase  mechanism  (Williams,  1983) the efficiency of 
which is limited and depends on the number of plasmalem- 
mal vesicles, on the plasma concentration of  the proteins and 
on their size, shape, and charge (Simionescu et al.,  1972; 
Ghinea  and Simionescu,  1985; Ghinea  and  Hasu,  1986; 
Ghinea,  1987; Simionescu and Ghinea,  1990). It has also 
been observed that plasma proteins  (for instance albumin) 
may interact in the plasmalemmal vesicles with low-affinity- 
binding proteins (Ghitescu et al., 1986; Milici et al., 1987; 
Ghinea et al.,  1988; Schnitzer et al.,  1988; Ghinea et al., 
1989). It seems unlikely that protein hormones,  which are 
present in blood at very low concentrations and which fluc- 
tuate rapidly in order to give sharp biological effects, could 
follow this  route.  Surprisingly  very little  information  is 
available on the transendothelial transport of  protein and gly- 
coprotein hormones. 
In the present study we have used both biochemical and 
morphological approaches to determine the transendothelial 
route of hCG towards its target Leydig cells in rat testis. We 
have observed its interaction with an endothelial cell mem- 
brane component which we have identified by immunocyto- 
chemistry  and  immunopurification  (see  Table II)  as  the 
LH/hCG receptor. Its interaction,  in different species, with 
several monoclonal anti-receptor antibodies (LHR729, 38, 
and 285) recognizing different epitopes (V. Hal, unpublished 
results), confirmed this identification. Furthermore, a recent 
study confirmed the presence  of LH/hCG receptor  in rat 
ovarian and testicular blood vessels (Bukovsky et al., 1993). 
The transcytosis of hCG occurs in several steps: the hor- 
mone molecules first bind to specific receptors expressed on 
the luminal front, then they are concentrated in coated pits 
and transferred via coated vesicles to an extensive smooth 
tubulo-vesicular  endosome  system  (at  present,  the  exact 
steps in the transition from coated vesicles to endosomes are 
not well characterized).  The hormone and the receptor are 
then directed  to the abluminal  front by means of smooth 
transcytotic vesicles that pinch off from the tubular exten- 
sions of  the endosomes. These vesicles became inserted into 
the abluminal endothelial plasma membrane and, finally, the 
hormone is released into the subendothelial space. 
Our results also indicate that a  small proportion  of the 
hCG-gold conjugate leaves the endosomes and enters the 
multivesicular bodies. This fraction of  hormone may thus be 
engaged in a pathway leading to its degradation.  However, 
there is a possibility that some of  the tracer is carded towards 
the abluminal cell surface by smooth transcytotic vesicles, 
derived  from the tubular  extensions of the multivesicular 
bodies. Such a mechanism has been reported for the transfer- 
tin receptor in other cell types (Harding et al., 1983; Hop- 
kins,  1983). 
The  dissociation  mechanism  of the  hormone-receptor 
complex on the abluminal cell surface is unknown. Covalent 
posttranslational  modifications of the receptor,  e.g., phos- 
phorylation (Hipkin et al.,  1993) and possible differences 
between the intraluminal pH of the transcytotic vesicles (de- 
rived from endosomes) and the physiological pH of  the inter- 
stitial fluid may induce reversible conformational changes in 
the LH/hCG receptor  molecule.  These  structural  modifi- 
cations would allow continuous hormone delivery and shut- 
fling of the receptor  across  the endothelial cells.  The re- 
internalization of the receptor on the endothelial abluminal 
cell surface seems to occur via coated pits and vesicles. 
The route followed by hormone-receptor complexes in en- 
dothelial cells differs from the endocytosis previously de- 
scribed in Leydig cells and in transfected L cells (Ghinea et 
al., 1992). In the latter the complexes are directed towards 
the lysosomes. The tubulo-vesicular endosomes seem to be 
the place where different sorting mechanisms orient the hor- 
mone-receptor complexes  along  different pathways. This 
suggests the existence in Leydig and in endothelial cells of 
different signals on the cytoplasmic domain of the receptor 
(for instance different phosphorylation patterns) or of inter- 
actions with different "sorting" proteins (Goud and McCaf- 
frey, 1991; Bomsel and Mostov, 1992). 
Transcytosis,  involving tubulo-vesicular  endosomes  has 
never, to our knowledge, been described in endothelial cells. 
However, such a mechanism has been observed in various 
epithelial cells for the transcytosis of  thyroglobulin (Herzog, 
1983), epidermal growth factor (Maratos-Flier et al., 1987), 
nerve  growth  factor (Siminoski  et al.,  1986), transferrin 
(Seddiki et al.,  1992), IgG (Rodewald and Kraehenbuhl, 
1984; Parham,  1989), IgM, and IgA (Geuze et al.,  1984; 
Hoppe et al., 1985; Mostov and Simister, 1985). In the latter 
case some of the sorting mechanisms discussed above have 
been elucidated: Casanova et al.  (1990) have shown that if 
the serine 664 of  the polymer IgA receptor is replaced by an 
alanine the receptor keeps its property of internalization but 
fails to be sorted efficiently out of  the endocytic route. Phos- 
phorylation of serine 664 is thus probably important for the 
correct  orientation  of the receptor  towards its transcytotic 
route. 
Although we have used polyvalent tracers (hCG-gold and 
LHR729-gold  complexes) to observe the fate of hormone 
and antibody, the morphological conclusions were consistent 
with other experiments involving iodinated or fluorescein- 
labeled monomeric equivalents. 
How general is the mechanism of receptor-mediated hor- 
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mine at present.  We have gathered some preliminary  evi- 
dence that hCG is transported through a similar mechanism 
in the ovarian microvasculature  (N.  Ghinea,  unpublished 
results).  Moreover,  receptors  for  insulin and  insulin-like 
growth factor II have previously been detected in blood ves- 
sels  and the possibility  of their  involvement in hormone 
transport  has  been  discussed  (King  and  Johnson,  1985; 
Duffy and Pardridge,  1987;  Bar et al.,  1990;  Pillion and 
Meezan, 1990; Moser et al., 1992; Partridge, 1992). How- 
ever, no specific mechanisms have been described and no ul- 
trastructural studies have been performed.  For low-density 
lipopmteins  and  for  transferrin,  involvement  of  specific 
receptors  in  the  transendothelial  transport  has  been  de- 
scribed (Vasile et al., 1983; Jefferies et al., 1984;  Soda and 
Tavassoli, 1984; Hashida et al., 1986; Kishimoto and Tavas- 
soli, 1987; Omoto et al., 1992). Taken together these obser- 
vations suggest that the mechanism described in the present 
study may be of more general significance.  Further studies 
will be necessary to establish if this transport mechanism 
may be regulated: for instance if there is a hormone induced 
down-regulation of the endothelial receptor which could de- 
crease hormone transport and contribute to the desensitiza- 
tion of hormone action. It will be also important to establish 
whether the receptor-mediated  transcytosis  is restricted to 
the endothelium of target organs or whether it also exists in 
hormone producing organs. In the latter case the transport 
of hormones would occur in the opposite direction (from the 
abluminal  endothelial  front  to the vascular  lumen).  Hor- 
mone transport may also display different characteristics  in 
fenestrated  endothelia  though protein  transport  does  not 
seem to occur through  the  fenestrae  (Simionescu et  al., 
1981). 
Our results have also shown that the anti-receptor antibod- 
ies can be actively transported  through  the testicular  en- 
dothelial barrier by the LH/hCG receptor-mediated  transcy- 
tosis system. Drug targeting using monoclonal antibodies is 
extensively  studied  (reviewed  in Goldberg,  1993;  Rubin, 
1993).  Very often  such antibodies  linked  to drugs  or to 
toxins prove very effective in vitro on model cell culture sys- 
tems but fail to be active in vivo in whole animals or in pa- 
tients. Various hypotheses have been discussed in such cases 
(reviewed in Jain, 1989) but very fewstudies have addressed 
the question of the accessibility of the tumor. Kemshead  et 
al. (1990) have shown that only 0.001% of a monoclonal anti- 
body gains access to the interstitial  space.  Dillman et al. 
(1981) injected anti-melanoma antibodies in patients and ob- 
served a very low concentration  in the tumors, contrasting 
with persisting  high concentrations  in blood. Thus an effi- 
cient transfer through the endothelial  barrier may be a pre- 
requisite  for the therapeutic activity  of such antibody con- 
jugates.  Yoshikawa and  Pardridge  (1992)  have used anti- 
transferrin receptor  antibodies  to enhance the activity of 
drug targeting  into brain  tumors.  The use of specific  en- 
dothelial transcytosis  systems and the enhancement  of the 
transport of  the antibodies by coinjection  of  hormones may 
be of great therapeutic interest. In the present study we have 
shown an  efficient  intratesticular  transfer  of the  anti-LH 
receptor antibody linked to fluorescein.  This is of course a 
preliminary observation and further studies of various prac- 
tical aspects (extensive analysis of tissue specificity  of trans- 
cytosis, hepatic  clearance  of antibodies,  etc.)  will have to 
be performed. 
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